Studies such as KEYNOTE-590 (11)/Checkmate-648 (12)/JUPITER-06 (13) have shown that immunotherapy provides significant clinical benefits for locally advanced ESCC, regardless of PD-L1 status. Here, CD274 is linked to esophageal squamous cell carcinoma.